{"filing":{"accession_number":"0001171843-26-004676","cik":"0001581178","ticker":"EPRX","company_name":"EUPRAXIA PHARMACEUTICALS INC.","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"f6k_071526.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1581178/000117184326004676/f6k_071526.htm"},"events":[{"id":18088,"run_id":16242,"accession_number":"0001171843-26-004676","anchor_item_number":"EX-99.1","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The exhibit discloses the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations effective July 13, 2026, and the elevation of Dr. Alex Therien to Executive Vice President, Research \u0026 Development. While the filing also mentions Amanda Malone's departure as Chief Scientific and Operating Officer, the primary announced action is the appointment of new executive leadership to support the company's clinical and commercial development. The material change report emphasizes these leadership updates as part of the company's evolution and operational restructuring.","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16793,"accession_number":"0001171843-26-004676","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The exhibit discloses the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations effective July 13, 2026, and the elevation of Dr. Alex Therien to Executive Vice President, Research \u0026 Development. While the filing also mentions Amanda Malone's departure as Chief Scientific and Operating Officer, the primary announced action is the appointment of new executive leadership to support the company's clinical and commercial development. The material change report emphasizes these leadership updates as part of the company's evolution and operational restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T17:26:37.192059+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16793,"accession_number":"0001171843-26-004676","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The exhibit discloses the appointment of Dr. Jeff Millard as Executive Vice President, Technical Operations effective July 13, 2026, and the elevation of Dr. Alex Therien to Executive Vice President, Research \u0026 Development. While the filing also mentions Amanda Malone's departure as Chief Scientific and Operating Officer, the primary announced action is the appointment of new executive leadership to support the company's clinical and commercial development. The material change report emphasizes these leadership updates as part of the company's evolution and operational restructuring.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T17:26:37.192059+00:00","company_name":"EUPRAXIA PHARMACEUTICALS INC.","ticker":"EPRX","filing_date":"2026-07-15"}]}